GlassScriptPhysician profile
Michelle Hathaway
NPI 1558798702
$6,177.97
in general payments reported to CMS, 2019-2025
24 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,099 · 2022: $880 · 2023: $1,540 · 2024: $1,484 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,040 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,039.53 |
| Education | $158.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,923.30 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $835.31 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $677.47 | 2021-2025 | Tezspire, Fasenra, Breztri |
| Mylan Specialty L.P. | $518.08 | 2021-2024 | Yupelri |
| Genzyme Corporation | $449.64 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $341.47 | 2021-2025 | Ofev, Spiriva Respimat, Jascayd |
| Philips North America LLC | $304.77 | 2021-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Grifols USA, LLC | $219.61 | 2021-2025 | Prolastin-C Liquid |
| Amgen INC. | $187.42 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $181.65 | 2021-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Novartis Pharmaceuticals Corporation | $67.83 | 2021-2024 | |
| Axsome Therapeutics, INC. | $66.02 | 2023-2025 | Sunosi |
| Inspire Medical Systems, INC. | $57.22 | 2023 | Inspire |
| Actelion Pharmaceuticals US, INC. | $42.94 | 2022-2024 | Opsumit, Uptravi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $42.28 | 2025 | Yupelri |
| Verona Pharma, INC. | $36.49 | 2025 | Ohtuvayre |
| Insmed, INC. | $33.29 | 2021-2022 | |
| Electromed, INC. | $29.15 | 2025 | Smartvest |
| Teva Pharmaceuticals USA, INC. | $24.57 | 2021 | |
| Mallinckrodt Hospital Products INC. | $16.03 | 2024 | Acthar |
| Jazz Pharmaceuticals INC. | $14.89 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.87 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.68 | 2025 | Alvesco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Hathaway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.